10x Science builds a platform that interprets complex mass spectrometry data using deterministic algorithms grounded in chemistry and biology alongside AI agents trained on spectrometry datasets. The product produces traceable analyses intended to meet regulatory-compliance needs and accelerate characterization of biologic drug candidates. The founders—David Roberts, Andrew Reiter, and Vishnu Tejas—came from a Stanford lab and trained the models to handle varied molecular data and explain their conclusions. 10x is currently working with major pharmaceutical companies, academic researchers, and service firms like Rilas Technologies. The company intends to use its $4.8M seed to hire engineers, further refine its models, and roll the platform out to more customers. No revenue, user, or valuation metrics were disclosed in the article.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026